LONDON (Reuters) - Patients who take medicines derived from blood plasma or urine are not at increased risk of catching Zika, even if the body fluids come from countries where the virus is prevalent, Europe's drugs regulator said on Wednesday.

WASHINGTON, Sept 21 (Reuters) - Shorthanded and ideologically divided, the U.S. Supreme Court has yet to take up any cases on politically sensitive social issues in its new term starting in October, instead showing a keen interest in more technical cases of importance to business such as disputes over intellectual property.

LONDON (Reuters) - AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product.

(Reuters Health) - For young adults on a long-term healthy diet and exercise program, tracking activity with a wearable device may not lead to additional weight loss, according to a new study.

BEIRUT (Reuters) - An air raid carried out overnight by Syrian or Russian warplanes killed four medical workers and at least nine rebel fighters near Aleppo, the Syrian Observatory for Human Rights monitoring group said on Wednesday.

WASHINGTON, Sept 21 (Reuters) - Shorthanded and ideologically divided, the U.S. Supreme Court has yet to take up any cases on politically sensitive social issues in its new term starting in October, instead showing a keen interest in more technical cases of importance to business such as disputes over intellectual property.

SHANGHAI (Reuters) - China had 232 chemical-related accidents from January to August this year, causing 199 deaths and 400 injuries, according to research from the environmental group Greenpeace published on Wednesday.

SEOUL (Reuters) - Sentiment at Asian companies edged up to its highest level in five quarters in July-September, boosted by signs that China's economy is stabilizing and as concerns about Britain's move to exit the European Union recede, a Thomson Reuters/INSEAD survey showed.

NEW YORK (Reuters) - Mylan NV faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the company’s rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.